Corcept Therapeutics (CORT) News and press releases

Analyst Expectations for Corcept Therapeutics's Future

26 May 23

Analyst Ratings

Truist Securities Maintains Hold on Corcept Therapeutics, Lowers Price Target to $26

26 May 23

News, Price Target, Analyst Ratings

Truist Securities analyst Gregory Fraser maintains Corcept Therapeutics (NASDAQ:CORT) with a Hold and lowers the price target from $28 to $26.

Corcept Therapeutics's Return On Capital Employed Overview

10 May 23

Earnings

HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $30 Price Target

4 May 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $30 price target.

Recap: Corcept Therapeutics Q1 Earnings

3 May 23

Earnings

Corcept Therapeutics Q1 EPS $0.14 Misses $0.19 Estimate, Sales $105.65M Beat $104.87M Estimate

3 May 23

Earnings, News

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.19 by 26.32 percent. This is a 30 percent decrease over earnings of $0.20 per share from

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023

11 Apr 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

SVB Leerink Initiates Coverage On Corcept Therapeutics with Market Perform Rating, Announces Price Target of $25

11 Apr 23

News, Price Target, Initiation, Analyst Ratings

SVB Leerink analyst Roanna Ruiz initiates coverage on Corcept Therapeutics (NASDAQ:CORT) with a Market Perform rating and announces Price Target of $25.

Benzinga Pro's Top 5 Stocks To Watch For Monday, April 10, 2023: TSLA, CORT, JPM, PXD, MODG

10 Apr 23

Pre-Market Outlook

Tesla (TSLA) - Several media outlets reported that Tesla cut US prices for the fifth time since January. Corcept Therapeutics (CORT) - Over the weekend a federal judge in

Short Volatility Alert: Corcept Therapeutics

5 Apr 23

Short Ideas, Trading Ideas

On Tuesday, shares of Corcept Therapeutics (NASDAQ: CORT) experienced volatile short activity. After the activity, the stock price went up +1.66% to $22.02. The overall sentiment for CORT has been Bullish.

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023

4 Apr 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Analyst Ratings for Corcept Therapeutics

4 Apr 23

Analyst Ratings

Piper Sandler Initiates Coverage On Corcept Therapeutics with Overweight Rating, Announces Price Target of $27

4 Apr 23

News, Price Target, Initiation, Analyst Ratings

Piper Sandler analyst David Amsellem initiates coverage on Corcept Therapeutics (NASDAQ:CORT) with a Overweight rating and announces Price Target of $27.

Corcept Therapeutics Initiates CATALYST Clinical Trial

28 Mar 23

Biotech, News, General

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 Apr 23

Earnings, Press Releases

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023. The

Corcept Therapeutics Announces Final Results of Tender Offer

5 Apr 23

Markets, Press Releases

MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine,

Corcept Therapeutics Announces Preliminary Results of Tender Offer

3 Apr 23

Health Care, Markets, Press Releases

MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine,

Corcept Therapeutics Initiates CATALYST Clinical Trial

28 Mar 23

Health Care, Press Releases

MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine,